一分钟看懂
这是一项关于乳腺癌的II 期研究，登记的药物或干预包括Culmerciclib；Aromatase Inhibitor (AI)，当前状态为招募中。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Culmerciclib；Aromatase Inhibitor (AI) · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 广州
公开的入选条件
- * Able to understand study procedures, voluntarily participate in the study, and provide written informed consent.
- * Female patients aged ≥18 and ≤70 years with histopathologically confirmed untreated unilateral primary invasive breast cancer.
- * Hormone-receptor positive (estrogen receptor immunohistochemical expression ≥10%), and HER2-negative (IHC 0-1+, or IHC 2+ with negative FISH test).
- * Tumor size \>2 cm or positive regional lymph nodes (TNM stage II-IIIA).
- * At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- * Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- * Adequate cardiac function meeting all of the following criteria:
- i. 12-lead electrocardiogram shows no abnormality or clinically insignificant changes requiring no medical intervention; ii. QTc interval ≤480 ms; iii. No history of torsades de pointes or other symptomatic QTc abnormalities; iv. Left-ventricular ejection frac
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07796880；登记信息更新于 2026-09-15。